Business Description
Achilles Therapeutics PLC
ISIN : US00449L1026
Share Class Description:
FRA:698: ADRDescription
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 26.67 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -29.6 | |||||
3-Year EPS without NRI Growth Rate | -28.7 | |||||
3-Year FCF Growth Rate | -10.7 | |||||
3-Year Book Growth Rate | -9.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.74 | |||||
9-Day RSI | 34.18 | |||||
14-Day RSI | 38.91 | |||||
6-1 Month Momentum % | 10.67 | |||||
12-1 Month Momentum % | -0.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.63 | |||||
Quick Ratio | 9.63 | |||||
Cash Ratio | 8.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 7.65 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -41.03 | |||||
ROA % | -36.28 | |||||
ROIC % | -235.13 | |||||
ROC (Joel Greenblatt) % | -321.14 | |||||
ROCE % | -44.25 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.26 | |||||
Price-to-Tangible-Book | 0.26 | |||||
EV-to-EBIT | 1.04 | |||||
EV-to-EBITDA | 1.08 | |||||
EV-to-FCF | 4.06 | |||||
Price-to-Net-Current-Asset-Value | 0.29 | |||||
Price-to-Net-Cash | 0.35 | |||||
Earnings Yield (Greenblatt) % | 96.15 | |||||
FCF Yield % | -53.14 |